AU2001245972A1 - N-heterocyclic derivatives as nos inhibitors - Google Patents

N-heterocyclic derivatives as nos inhibitors

Info

Publication number
AU2001245972A1
AU2001245972A1 AU2001245972A AU4597201A AU2001245972A1 AU 2001245972 A1 AU2001245972 A1 AU 2001245972A1 AU 2001245972 A AU2001245972 A AU 2001245972A AU 4597201 A AU4597201 A AU 4597201A AU 2001245972 A1 AU2001245972 A1 AU 2001245972A1
Authority
AU
Australia
Prior art keywords
heterocyclic derivatives
nos inhibitors
compounds
inhibitors
nitric oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001245972A
Inventor
David D Davey
Eric Pham
Gary B Phillips
Wei Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2001245972A1 publication Critical patent/AU2001245972A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

N-Heterocyclic derivatives selected from the group consisting of the following formulae:where Z1, Z2, Z3, R1, R2, R3, R4, R5 and R6 are described herein, are useful as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.
AU2001245972A 2000-03-27 2001-03-26 N-heterocyclic derivatives as nos inhibitors Abandoned AU2001245972A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19216800P 2000-03-27 2000-03-27
US60192168 2000-03-27
US09814787 2001-03-22
US09/814,787 US6525051B2 (en) 2000-03-27 2001-03-22 N-heterocyclic derivatives as NOS inhibitors
PCT/US2001/009481 WO2001072744A1 (en) 2000-03-27 2001-03-26 N-heterocyclic derivatives as nos inhibitors

Publications (1)

Publication Number Publication Date
AU2001245972A1 true AU2001245972A1 (en) 2001-10-08

Family

ID=26887800

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001245972A Abandoned AU2001245972A1 (en) 2000-03-27 2001-03-26 N-heterocyclic derivatives as nos inhibitors

Country Status (13)

Country Link
US (1) US6525051B2 (en)
EP (1) EP1268471B1 (en)
JP (1) JP2003528871A (en)
AT (1) ATE252097T1 (en)
AU (1) AU2001245972A1 (en)
DE (1) DE60101000T2 (en)
DK (1) DK1268471T3 (en)
ES (1) ES2208578T3 (en)
HK (1) HK1053834A1 (en)
NO (1) NO20024614L (en)
PT (1) PT1268471E (en)
TR (1) TR200302268T4 (en)
WO (1) WO2001072744A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US7012098B2 (en) * 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
IL162189A0 (en) * 2001-11-30 2005-11-20 Synta Pharmaceuticals Corp Pyrimidine compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
EP1795192A3 (en) * 2002-04-30 2008-05-07 Bayer Schering Pharma Aktiengesellschaft 1-(Pyridazin-3-yl)-imidazole derivatives as inhibitors of nitric oxide synthase (NOS)
MXPA05001096A (en) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds.
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GEP20084357B (en) 2002-12-20 2008-04-29 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1626725A4 (en) * 2003-05-29 2006-06-14 Synta Pharmaceuticals Corp Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
US8178671B2 (en) * 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
BRPI0510963A (en) 2004-05-14 2007-11-20 Pfizer Prod Inc pyrimidine derivatives for the treatment of abnormal cell growth
CA2566477A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP1751142A1 (en) 2004-05-14 2007-02-14 Pfizer Products Incorporated Pyrimidines derivatives for the treatment of abnormal cell growth
WO2006007532A2 (en) * 2004-07-01 2006-01-19 Synta Pharmaceuticals Corp. 2-substituted heteroaryl compounds
ATE540035T1 (en) * 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc SPIRO-2,4-PYRIMIDINEDIAMINE COMPOUNDS AND USES THEREOF
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
PL2354126T3 (en) * 2005-01-14 2014-03-31 Chemocentryx Inc Heteroaryl sulfonamides and CCR2
DK1856135T3 (en) 2005-01-19 2010-04-12 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
WO2007039578A1 (en) * 2005-10-05 2007-04-12 Nycomed Gmbh Imidazolyl-substituted azabenzophenone compounds
EA016679B1 (en) 2007-04-18 2012-06-29 Пфайзер Продактс Инк. Sulfonyl amide derivatives for the treatment of abnormal cell growth
US7884110B2 (en) 2007-07-12 2011-02-08 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
NZ589315A (en) * 2008-04-16 2012-11-30 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
PT2300013T (en) 2008-05-21 2017-10-31 Ariad Pharma Inc Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
BR112013027734A2 (en) 2011-05-04 2017-08-08 Ariad Pharma Inc compounds for inhibition of cell proliferation in egfr-driven cancers, method and pharmaceutical composition
US8877760B2 (en) 2011-11-23 2014-11-04 Portola Pharmaceuticals, Inc. Substituted pyrazine-2-carboxamide kinase inhibitors
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
KR20190088513A (en) 2016-11-23 2019-07-26 케모센트릭스, 인크. Treatment of local segmental glomerulosclerosis
JP7301758B2 (en) * 2017-03-13 2023-07-03 インペティス・バイオサイエンシーズ・リミテッド Fused bicyclic compounds, compositions and applications thereof
US10758540B2 (en) 2017-10-11 2020-09-01 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
KR102563834B1 (en) * 2021-06-28 2023-08-04 순천대학교 산학협력단 Novel compound for inducing apoptosis and composition for anticancer comprising the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339875A (en) 1986-08-05 1988-02-20 Nissin Food Prod Co Ltd Pyrimidine derivative
DE4118720A1 (en) 1991-06-07 1992-12-10 Bayer Ag SUBSTITUTED IMIDAZOLINYLPYRIMIDINE
EP0629622B1 (en) 1992-02-28 1998-11-11 Zenyaku Kogyo Kabushikikaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
DK0640599T3 (en) 1993-08-26 1998-09-28 Ono Pharmaceutical Co 4-aminopyrimidine derivatives
US5426110A (en) 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
WO1996014842A1 (en) 1994-11-15 1996-05-23 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
PT813525E (en) * 1995-03-10 2004-02-27 Berlex Lab BENZAMIDINE DERIVATIVES AND THEIR USE AS ANTICOAGULANTS
DE19541146A1 (en) * 1995-10-25 1997-04-30 Schering Ag Imidazole derivatives and their use as nitric oxide synthase inhibitors
ZA977427B (en) 1996-09-04 1998-03-02 Dainippon Pharmaceutical Co 2,4-disubstituted pyrimidine derivative, process for preparing the same, and a pharmaceutical composition containing the same.
EP0946587A2 (en) * 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
IL131475A0 (en) 1997-02-19 2001-01-28 Berlex Lab N-heterocyclic derivatives as nos inhibitors

Also Published As

Publication number Publication date
US6525051B2 (en) 2003-02-25
JP2003528871A (en) 2003-09-30
DK1268471T3 (en) 2004-02-09
US20020010190A1 (en) 2002-01-24
PT1268471E (en) 2004-03-31
NO20024614L (en) 2002-11-26
EP1268471B1 (en) 2003-10-15
TR200302268T4 (en) 2004-01-21
EP1268471A1 (en) 2003-01-02
DE60101000D1 (en) 2003-11-20
DE60101000T2 (en) 2004-07-29
ATE252097T1 (en) 2003-11-15
WO2001072744A1 (en) 2001-10-04
ES2208578T3 (en) 2004-06-16
HK1053834A1 (en) 2003-11-07
NO20024614D0 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
AU2001245972A1 (en) N-heterocyclic derivatives as nos inhibitors
UA72930C2 (en) N-heterocyclic compounds derivatives as inhibitors of nitric oxide synthase (nos)
CA2281545A1 (en) N-heterocyclic derivatives as nos inhibitors
AU2002239344A1 (en) Pyrazolopyridines
AU2003228678A1 (en) 1-substituted imidazole derivatives as nos inhibitors
CA2390649A1 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
WO2003095455A3 (en) Substituted pyrazolopyrimidines
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
WO2002048148A3 (en) Pyrazolopyridine derivatives
IL173895A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
IL173809A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
WO2003080631A3 (en) Plasma carboxypeptidase b inhibitors
AU2002248531A1 (en) Pyrazolopyriadine derivatives
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
WO2004093796A3 (en) Lactam derivatives and methods of their use
WO2004054983A3 (en) 1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors